A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years

A cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the prevention of pneumococcal disease among Mexican adults aged ≥60 years

Current standard of care (SoC) for the prevention of pneumococcal disease among Mexican adults aged ≥60 years is a sequential regimen of pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPSV23). This study estimated the...

Full description

Saved in:
Bibliographic Details
Main Authors: Jose Luis Huerta, An Ta, Elizabeth Vinand, Gustavo Ivan Torres, Warisa Wannaadisai, Liping Huang
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Vaccine: X
Subjects:
Pneumococcal disease
PCV20
Pneumococcal conjugate vaccine
Adult
Mexico
National immunization program
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136225000762
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items